Recent Updates
Recently added Catalysts
QGEN Positive Sentiment

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

Key Takeaway: QIAGEN has received FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, marking the first panel designed for bloodstream infections. This approval broadens QIAGEN's offerings in the syndromic testing market, now covering four major infectious disease areas. The panel aims to enhance diagnostic capabilities in critical infection management.

Market Sentiment Analysis

POSITIVE FACTORS

  • QIAGEN's QIAstat-Dx panel receives FDA clearance.
  • This is the first panel for bloodstream infections approved.
  • Expands QIAGEN's syndromic testing portfolio significantly.

Full Press Release Details

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The clearance expands QIAGEN’s U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is availa

Frequently Asked Questions

What is the QIAstat-Dx BCID GPF Plus AMR Panel?

It is the first QIAstat-Dx panel cleared by the FDA for diagnosing bloodstream infections.

How does this clearance benefit QIAGEN?

It expands their U.S. syndromic testing portfolio into bloodstream infection diagnostics.

What areas does the QIAstat-Dx platform cover?

The platform now covers four major infectious disease areas, including bloodstream infections.

Last updated: Aug 10, 2026